RecruitingPHASE1, PHASE2NCT05908409
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Studying Multiple myeloma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IDP Discovery Pharma S.L.
- Principal Investigator
- Enrique Ocio San Miguel, MD, PhDHospital Universitario Marqués de Valdecilla
- Intervention
- IDP-121(drug)
- Enrollment
- 37 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (11)
- Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
- Hospital Universitario de Salamanca, Salamanca, Castille and León, Spain
- Hospital Universitari Vall d'hebron, Barcelona, Spain
- Hospital Durán i Reynals - ICO L´Hospitalet, Barcelona, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Hospital Universitario La Paz, Madrid, Spain
- Hospital Universitario Puerta de Hierro, Madrid, Spain
- Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
- Hospital Universitario Virgen del Rocio, Seville, Spain
- Hospital de Clinico Universitario de Valencia, Valencia, Spain
- Hospital Universitario Miguel Servet, Zaragoza, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05908409 on ClinicalTrials.govOther trials for Multiple myeloma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07225738A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsCity of Hope Medical Center
- RECRUITINGPHASE3NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaTakeda
- RECRUITINGPHASE4NCT07094048Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell EngagerCHU de Quebec-Universite Laval
- RECRUITINGNANCT07226934An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersWashington University School of Medicine
- RECRUITINGEARLY PHASE1NCT07294625A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1NCT07179679A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsGuangzhou Gloria Biosciences Co., Ltd.
- RECRUITINGNANCT07359014Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple MyelomaSecond Affiliated Hospital, School of Medicine, Zhejiang University